Home » Market News » DirectorsTalk Highlights » Webinar: Affimer® anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics
Avacta Group Plc

Webinar: Affimer® anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics

In this free webinar, Principal Assay Scientist Dr. Amanda Nicholl presented data from the recently published paper in Biotechniques, ‘Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics’.

The use of anti-idiotypic Affimer reagents in this study showed a number of advantages to their use as critical reagents compared to antibodies, including:

  • High target specificity and low cross-reactivity.
  • Lot-to-lot reproducibility and calibration curve metrics meeting FDA criteria for bioanalytical assay reagents.
  • Increased dynamic range and reduced matrix effect compared to commercially available anti-idiotypic Fab fragments..
  • Use of a universal detection system to offer simple and speedy assay design and development.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.